Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Interviews

Plotting The Path For Pharma To Maintain New-Found Trust

Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.

Strategy Companies

Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'

The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.

South Korea Financing

Ionis Invests For The Future In New Technologies, Manufacturing Innovation

Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.

Innovation Platform Technologies

Ionis Finds Its Footing Ahead Of Its First Big Commercial Step

Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.

Strategy Launches

Podcast: What Does The Pfizer/Seagen Merger Mean For M&A In 2023?

Scrip overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and its ramifications for the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.

Deals M & A

Emocog Setting The Standard For Cognitive Decline DTx in Korea

In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.

South Korea Digital Health

Belgium's Sequana Sits At Junction Between Pharma And Medtech

The company’s dual drug-device development pipeline is progressing well, especially its direct sodium removal therapy for congestive heart failure.

Cardiovascular Business Strategies

Kyowa Kirin’s North America Expansion Progresses With Crysvita Commercial Takeover

The Japanese pharma has taken over commercialization of the rare disease drug from Ultragenyx under a planned transition and as part of a broader growth strategy in North America.

North America Business Strategies

Swiss Talent And Innovation ‘Needs More Financing To Flourish’

With excellent academic centers and a thriving start-up scene, Switzerland’s biotech scene has garnered significant interest in recent years. However, without being a priority for EU funds, the sector remains reliant on foreign cash and needs a funding push from within to boost success.

Financing Switzerland

The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma’s Past CEOs

As big pharma braces for a new wave of patent expiries, we speak to two former industry chiefs – Novartis’s Joe Jimenez and Schering-Plough’s Fred Hassan – about the approach they took in similar circumstances.

Strategy Sales & Earnings

Novartis Confident About Transforming CSU Landscape

With its BTK inhibitor remibrutinib advancing through Phase III trials and work getting started on a CAR-T therapy for lupus, Novartis’s Marie-France Tschudin tells Scrip that the Swiss major’s immunology pipeline is in a healthy state.

Immune Disorders Research & Development

Novartis Committed To Carving Out More Indications For Cosentyx

The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”

Immune Disorders Business Strategies
See All
UsernamePublicRestriction

Register